- Home
- FINW vs CRVS Comparison
FINW vs CRVS Comparison
Compare FINW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CRVS
- Stock Information
- Founded
- FINW 1999
- CRVS 2014
- Country
- FINW United States
- CRVS United States
- Employees
- FINW N/A
- CRVS N/A
- Industry
- FINW Commercial Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- CRVS Health Care
- Exchange
- FINW Nasdaq
- CRVS Nasdaq
- Market Cap
- FINW 212.8M
- CRVS 516.0M
- IPO Year
- FINW 2021
- CRVS 2016
- Fundamental
- Price
- FINW $15.33
- CRVS $5.10
- Analyst Decision
- FINW Buy
- CRVS Strong Buy
- Analyst Count
- FINW 3
- CRVS 5
- Target Price
- FINW $18.67
- CRVS $12.38
- AVG Volume (30 Days)
- FINW 19.3K
- CRVS 1.7M
- Earning Date
- FINW 01-30-2025
- CRVS 11-12-2024
- Dividend Yield
- FINW N/A
- CRVS N/A
- EPS Growth
- FINW N/A
- CRVS N/A
- EPS
- FINW 1.06
- CRVS N/A
- Revenue
- FINW $69,509,000.00
- CRVS N/A
- Revenue This Year
- FINW N/A
- CRVS N/A
- Revenue Next Year
- FINW $10.13
- CRVS N/A
- P/E Ratio
- FINW $14.71
- CRVS N/A
- Revenue Growth
- FINW 4.87
- CRVS N/A
- 52 Week Low
- FINW $8.72
- CRVS $1.30
- 52 Week High
- FINW $20.50
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FINW 35.07
- CRVS 36.16
- Support Level
- FINW $15.51
- CRVS $4.93
- Resistance Level
- FINW $16.65
- CRVS $6.47
- Average True Range (ATR)
- FINW 0.71
- CRVS 0.40
- MACD
- FINW -0.07
- CRVS 0.06
- Stochastic Oscillator
- FINW 0.00
- CRVS 29.74
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).